Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tamibarotene + decitabine for relapsed/refractory pediatric solid tumors and neuroblastoma
jRCT2051190055Phase 2Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Aug 2018
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tamibarotene and decitabine in pediatric solid tumors and neuroblastoma (2 cohorts), sponsored by Japan Agency for Medical Research and Development. Primary endpoints: Event rate of dose-limiting toxicity and Progression-free survival. Started Aug 2018; status: completed.
02
Drugs
tamibarotenedecitabine
03
Conditions
pediatric solid tumorsneuroblastoma
Beyond the preview
Go deeper on jRCT2051190055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051190055.